Skip to content

Randomized controlled clinical trial of acupuncture and lornoxicam in the treatment of acute renal colic

Randomized controlled clinical trial of acupuncture and lornoxicam in the treatment of acute renal colic

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026517
Enrollment
Unknown
Registered
2019-10-13
Start date
2019-08-13
Completion date
Unknown
Last updated
2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal colic

Interventions

experimental group:acupuncture + normal saline
control group:placebo acupuncture+lornoxicam

Sponsors

Lanzhou University Second Hospital (LUSH)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male or female, aged 18 to 75 years; 2. Diagnosed with ureteral calculi by B-ultrasound or KUB or CT examination, ureteral stone involvement is not limited (whether upper, middle or lower segment or left or right side of ureter); 3. Signs and symptoms of renal colic, such as gross or microscopic hematuria; 4. No other analgesics were used before the visit; 5. VAS (Visual Analogue Score) before treatment =3 points; 6. There are no cuts, ulcers, varicose veins or other conditions not suitable for acupuncture 7. Exclude other acute abdomen disease (such as renal or ureteral tumor, acute appendicitis, gastrointestinal colic or ovarian pedicle torsion, etc.); 8. Sign informed consent and volunteer to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Ureteral stricture and ureteral malformation; 2. Patients with double J tube or stone street after extracorporeal shock wave lithotripsy (ESWL); 3. Previous history of severe heart disease, pulmonary dysfunction, renal insufficiency or asthma; 4. Septic shock; 5. Previous mental illness and cognitive impairment; 6. Pregnant woman, breast feeding women or menstruating woman. 7. Patients with hypersensitivity to lornoxicam, active gastrointestinal ulcer, history of gastrointestinal bleeding or perforation after using NSAIDs; 8. Needle sickness, coagulation disorder, long-term use of anticoagulant drugs, sedatives, analgesics and antidepressants; 9. Other conditions considered unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
Short-term efficiency;Total amount of supplemental drugs;Incidence of adverse reactions;VAS score;

Countries

China

Contacts

Public ContactWang Zhiping, Liu Xinguo
erywzp@lzu.edu.cn+86 13893131697; 15955603799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026